Lowest Price Guaranteed From USD 4,799
Published
July 2023
Pages
407
View Count
153686
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The ADC technology market, comprising of ADC linker and antibody conjugation technologies is expected to grow at compounded annual growth rate (CAGR) of ~15% during the forecast period. Antibody drug conjugates have emerged as a promising alternative to the conventional anti-cancer therapies. Till date, around 14 ADCs have received the USFDA approval, while over 420 antibody drug conjugates are currently being evaluated under different stages of development. Antibody drug conjugate is a complex and versatile class of biotherapeutics, in which linker moiety is attached to the cytotoxic payload. However, the complex structure and design of antibody drug conjugates poses a greater challenge in overall tolerability and efficacy of the molecule. As a result, more advanced and efficacious antibody drug conjugate technology is required to generate the controlled assembly of antibody drug conjugates while maintaining tolerability and safety profiles. Antibody / ADC conjugation technologies generally involve modification / engineering of an antibody in order to conjugate it with a payload / linker-drug moiety. On the other hand, ADC linker technologies involve development of a structural moiety to link the payload with an antibody in a reliable manner with desired payload delivery mechanics. These technologies are optimized to produce homogenous antibody drug conjugate with high drug to antibody ratio (DAR). In fact, ADCs developed using these technologies have demonstrated improved stability and efficacy in tumor micro-environment.
Homogenous ADCs with optimized linker technologies offer reduced immunogenicity, enabling the targeted delivery of linker-payload complex at the desired site without having any side effects. Owing to the aforementioned advantages, several start-ups and established players have entered the field of ADC linker and conjugation technologies, offering novel conjugation / bioconjugation technologies, more potent payloads and advanced linker chemistries. These players have inked several licensing agreements to advance their ADC development programs. It is worth mentioning that researchers and antibody drug conjugate developers are actively relying on ADC linker and conjugation technology companies that offer technical expertise and experience in this market. Driven by the growing demand for antibody drug conjugates, the ADC linker and conjugation technologies market is anticipated to witness substantial market growth during the forecast period.
The Antibody Drug Conjugates: Focus on ADC Linker and Conjugation Technologies (2nd Edition) - Distribution by Generation of Technology (Third-Generation, Second-Generation and Next-Generation), Type of Conjugation (Chemical, Chemoenzymatic and Chemical), Type of Linker (Cleavable and Non-Cleavable), Type of Payment Model Adopted (Upfront Payments and Milestone Payments), and Key Geographical Regions (North America, Europe, and Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035 market report features an extensive study of the current market landscape, market size and future opportunities associated with the ADC linker and antibody conjugation industry, during the given forecast period. The market report highlights efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the ADC technology market are briefly discussed below.
In 2000, the USFDA approved the first ADC, Mylotarg. However, it was withdrawn voluntarily from the market due to safety concerns and poor clinical benefits of the product. With continued research in the area of ADCs, innovators have identified various factors that determine the success of an antibody drug conjugate; these include structure and design of an antibody drug conjugate, systemic toxicity, validation of tumor biomarkers, choice of antibody and potency of the payload. The challenges associated with conventional drug products have led to the development of advanced ADC linker and ADC conjugation technologies. These technologies have the potential to develop antibody drug conjugates with improved stability and toxicity profile, while maintaining efficient release of the cytotoxic payload at the desired location. The most important characteristic of these technologies is the production of controlled, homogenous ADCs, which are site-selective and can be utilized as a targeted anti-cancer therapy. We anticipate that the growing demand for targeted, stable and non-toxic ADCs will continue to drive the adoption and market growth of ADC linker technology and antibody conjugation technologies for development of antibody drug conjugates during the forecast period.
The ADC technologies market landscape features an extensive list of over 65 large, mid-sized and small companies that offer more than 95 ADC linker and conjugation technologies. These platforms include linker technologies, linker-payload technologies and antibody conjugation technologies for the development of ADC. It has been observed that the majority of the antibody drug conjugates generated via these ADC technologies are site specific, have high tolerability and precise DAR ratio. In addition, we believe that third-generation technologies are poised to play a significant role in shaping the future market landscape, by enabling the development of new therapeutic modalities that were previously considered unattainable. The constant evolution of ADC linkers and conjugation technologies will support the development of novel and more efficacious ADCs. In turn, the growing ADC therapy market will drive the demand for these technologies, contributing to substantial CAGR of ADC technology market during the forecast period.
The ADC technology market, comprising of ADC linker and antibody conjugation technologies is expected to grow at a CAGR of ~15% during the forecast period. Driven by the growing interest of stakeholders in addressing the efficiency and safety related concerns with antibody drug conjugates, the ADC linker and conjugation technologies market is anticipated to witness tremendous market growth in the foreseen future.
Based on mechanism of drug release, the linkers are categorized as cleavable or non cleavable linkers. Majority of the approved ADCs use cleavable linkers and based on the current late-stage pipeline of ADCs, the global ADC technology market is anticipated to be driven by cleavable linkers in the short term.
Close to 80% of the market share is estimated to be captured by companies based in North America and Europe. This can be attributed to the escalating partnership activity in these regions. It is interesting to note that 78% of the total deals were inked by players based in North America and Europe during the time period, 2014-2023. Further, some of the companies based in these developed regions, such as Mersana Therapeutics, Seattle Genetics and Zymeworks offer several antibody conjugation and ADC linker technology / platforms. These platforms are either second-generation or third-generation technologies that offer chemical site specific conjugation. Moreover, all these players have in-house ADC portfolio for testing the potential of their technologies and resulting in the development of innovative cancer therapies.
The growing demand for antibody drug conjugates for the treatment of various forms of cancer, especially breast cancer, has paved the way for continued innovation in antibody conjugation technologies. In order to access these advanced ADC technologies for the development of antibody drug conjugate, several business deals have been inked over the past few years. It is interesting to note that technology out-licensing and collaborative research are the most popular type of business models adopted by stakeholders in this industry. It is worth highlighting that Synaffix has received / is likely to receive close to USD 5.5 billion from out licensing their ADC conjugation platform. In June 2023, Lonza acquired Synaffix, getting access to the latter’s ADC technologies for payload and site-specific linkers. Another company, Mersana Therapeutics expects to receive nearly USD 2 billion in total payments from their collaborative research efforts with several stakeholders engaged in ADC development. Substantial investments like these, along with ongoing technological innovations, will act as the key driver behind the evolution of ADC linker and antibody conjugation technologies market during the forecast period.
In recent years, several partnerships have been inked by various stakeholders in order to consolidate their presence and enhance their capabilities and product portfolio to meet the growing demand for antibody drug conjugates. In fact, the partnership activity has witnessed a CAGR of ~30% in the past three years. Licensing agreements, product development agreements, and research and development agreements are the most common types of partnerships that have been inked in this industry.
In March 2022, Seattle Genetics entered into a research and development agreement with Sanofi for the development of three targets, focused on targeting cancer. In addition, it was observed that Mersana Therapeutics has signed several deals over the past few years for the development of various ADC candidates, targeting a wide array of cancers, including breast cancer, gastric cancer and non-small cell lung cancer. The growing interest in novel antibody drug conjugates and rising number of deals focused on advancing conventional therapies for targeting various oncological indications will continue to drive the ADC technology market over the coming years.
Examples of key players engaged in ADC technology industry (which have also been profiled in this report) include (in alphabetical order), Alteogen, Ambrx, Antikor, Catalent Biologics, Heidelberg Pharma, Iksuda Therapeutics, LegoChem Biosciences, Mersana Therapeutics, NBE-Therapeutics, Seattle Genetics and Sutro Biopharma. This market report includes an easily searchable, excel database of all the companies providing ADC technology related to ADC linkers or ADC conjugation worldwide.
Several recent developments have taken place in the field of ADC technology. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The market report presents an in-depth analysis of the various firms / organizations that are engaged in ADC technology market, across different segments, as defined in the table below:
| Key Report Attributes | Details | |
| Forecast Period | 2023 – 2035 | |
|
Historical Period |
2017-2022 |
|
|
CAGR |
~15% |
|
|
Generation of Technology |
|
|
|
Type of Conjugation |
|
|
|
Type of Linker |
|
|
|
Type of Payment Model Adopted |
|
|
| Key Geographical Regions |
|
|
|
Key Companies Profiled |
(Full list of 65+ companies captured in the market landscape analysis of the report) |
|
|
Customization Scope |
15% Free Customization Option | |
| Powerpoint Presentation (Complimentary) |
Available |
|
|
Excel Data Packs |
|
|
The market report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry. Amongst other elements, the market research report includes:
The opinions and insights presented in the report were influenced by our discussions with senior stakeholders in the industry. The market research report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2 Antibody Drug Conjugates (ADCs)
3.2.1 Components of ADCs
3.2.1.1 Antibody
3.2.1.2 Cytotoxin
3.2.1.3 Linker
3.3. Advantages of ADCs Over Conventional Therapeutics
3.4. ADC Linker Technologies
3.4.1. Non-cleavable Linkers
3.4.2. Cleavable Linkers
3.4. ADC Conjugation Technologies
3.4.1. Chemical Conjugation
3.4.2. Enzymatic Conjugation
3.5. Future Perspectives
4. ADC LINKER AND CONJUGATION TECHNOLOGIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Linker and Conjugation Technologies: Overall Market Landscape
4.2.1. Analysis by Type of Technology
4.2.2. Analysis by Availability of Licensing
4.3. ADC Conjugation Technologies
4.3.1. Analysis by Generation of Technology
4.3.2. Analysis by Site Specificity
4.3.3. Analysis by Type of Conjugation
4.3.4. Analysis by Drug Antibody Ratio
4.3.5. Analysis by Compatible Linker
4.3.6. Analysis by Conjugation Chemistry
4.3.7. Analysis by Conjugation Site
4.4. ADC Linker and ADC Linker-Payload Technologies
4.4.1. Analysis by Type of Linker
4.5. ADC Linker and Conjugation Technology Providers
4.5.1. Analysis by Year of Establishment
4.5.2. Analysis by Company Size
4.5.3. Analysis by Location of Headquarters
4.5.4. Analysis by Year of Establishment and Location of Headquarters
4.5.5. Analysis by Company Size and Location of Headquarters
4.6. ADC Conjugation Technologies Service Providers
5. TECHNOLOGY COMPETITIVENESS ANALYSIS
5.1 Chapter Overview
5.2 Assumptions and Key Parameters
5.3 Methodology
5.4 ADC Linker and Conjugation Technologies: Technology Competitiveness Analysis
5.4.1 Technologies Offered by Small Companies
5.4.2 Technologies Offered by Mid-sized Companies
5.4.3 Technologies Offered by Large Companies
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Companies Headquartered in North America
6.2.1. Ambrx
6.2.1.2. Company Overview
6.2.1.3. Financial Information
6.2.1.4. Technology Portfolio
6.2.1.5. Recent Developments and Future outlook
6.2.2. Catalent Biologics
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Technology Portfolio
6.2.2.4. Recent Developments and Future outlook
6.2.3. Mersana Therapeutics
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Technology Portfolio
6.2.3.4. Recent Developments and Future outlook
6.2.4. Seagen
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Technology Portfolio
6.2.4.4. Recent Developments and Future outlook
6.2.5. Sutro Biopharma
6.2.5.1. Company Overview
6.2.5.2. Financial Information
6.2.5.3. Technology Portfolio
6.2.5.4. Recent Developments and Future outlook
6.3. Companies Headquartered in Europe
6.3.1. Antikor Biopharma
6.3.1.1. Company Overview
6.3.1.2. Technology Portfolio
6.3.1.3. Recent Developments and Future outlook
6.3.2. Iksuda Therapeutics
6.3.2.1. Company Overview
6.3.2.2. Technology Portfolio
6.3.2.3. Recent Developments and Future outlook
6.3.3. Heidelberg Pharma
6.3.3.1. Company Overview
6.3.3.2. Financial Information
6.3.3.3. Technology Portfolio
6.3.3.4. Recent Developments and Future outlook
6.3.4. LinXis Biopharmaceuticals
6.3.4.1. Company Overview
6.3.4.2. Technology Portfolio
6.3.4.3. Recent Developments and Future outlook
6.3.5. NBE-Therapeutics
6.3.5.1. Company Overview
6.3.5.2. Technology Portfolio
6.3.5.3. Recent Developments and Future outlook
6.4. Companies Headquartered in Asia-Pacific and Rest of the World
6.4.1. Alteogen
6.4.1.1. Company Overview
6.4.1.2. Technology Portfolio
6.4.1.3. Recent Developments and Future outlook
6.5.2. LegoChem Biosciences
6.5.2.1. Company Overview
6.5.2.2. Technology Portfolio
6.5.2.3. Recent Developments and Future outlook
7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. ADC Linker and Conjugation Technologies: Patent Analysis
7.3.1. Analysis by Publication Year
7.3.2. Analysis by Application Year
7.3.3. Analysis by Annual Number of Granted Patents and Patent Applications
7.3.4. Analysis by Patent Jurisdiction
7.3.5. Analysis by CPC Symbols and Sections
7.3.6. Analysis by Type of Applicant
7.3.7. Leading Industry Players: Analysis by Number of Patents
7.3.8. Leading Non-Industry Players: Analysis by Number of Patents
7.3.9. Leading Patent Assignees: Analysis by Number of Patents
7.4. Patent Benchmarking Analysis
7.4.1. Analysis by Patent Characteristics
7.5. Patent Valuation
7.6. Leading Patents by Number of Citations
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADC Linker and Conjugation Technologies: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partnership
8.3.4. Analysis by Type of Partnership and Generation of Technology
8.3.5. Analysis by Type of Partnership and Type of Linker
8.3.6. Analysis by Type of Partnership and Type of Conjugation
8.3.7. Analysis by Type of Partner
8.3.8. Analysis by Year of Partnership and Type of Partner
8.3.9. Analysis by Type of Partnership and Type of Partner
8.3.10. Analysis by Target Therapeutic Area(s)
8.3.11. Most Active Players: Analysis by Number of Partnerships
8.3.12. Most Popular Technologies: Analysis by Number of Partnerships
8.4. Regional Analysis
8.4.1. Local and International Agreements
8.4.12. Intercontinental and Intracontinental Agreements
9. BUSINESS MODEL ANALYSIS
9.1. Chapter Overview
9.2 Business Strategies
9.4. ADC Linker and Conjugation Technology Providers: Business Strategy Analysis
9.4.1. Analysis by Purpose of Partnership
9.4.2. Analysis by Year of Partnership and Purpose of Partnership
9.4.3. Analysis by Type of Business Strategy Adopted
9.4.4. Analysis by Purpose of Partnership and Type of Business Strategy Adopted
9.4.5. Analysis by Upfront and Milestone Payments
9.4.6. Analysis by Type of Business Strategy Adopted and Deal Value
9.5. Most Active Players: Analysis by Number of Partnerships
9.5.1. Synaffix
9.5.1.1. Analysis by Purpose of Partnership
9.5.1.2. Analysis of Technology Out-Licensing Deals by Deal Value
9.5.2. LegoChem Biosciences
9.5.2.1. Analysis by Purpose of Partnership
9.5.2.2. Analysis by Year of Partnership and Business Strategy Adopted
9.5.2.3. Analysis of Technology Out-Licensing Deals by Amount of Investment
9.5.3. Catalent Biologics
9.5.3.1. Analysis by Purpose of Partnership
9.5.3.2. Analysis by Year of Partnership and Business Strategy Adopted
9.5.4. Sutro Biopharma
9.5.4.1. Analysis by Purpose of Partnership
9.5.4.2. Analysis by Year of Partnership and Business Strategy Adopted
9.5.4.3. Analysis of Technology Out-Licensing Deals by Deal Value
9.5.5. Heidelberg Pharma
9.5.5.1. Analysis by Purpose of Partnership
9.5.5.2. Analysis by Year of Partnership and Business Strategy Adopted
9.5.6. Mersana Therapeutics
9.5.6.1. Analysis by Purpose of Partnership
9.5.6.2. Analysis by Year of Partnership and Business Strategy Adopted
9.7. Concluding Remarks
10. LIKELY PARTNERS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions / Key Parameters
10.3. Scope and Methodology
10.4. Potential Strategic Partners in North America
10.4.1. Most Likely Partners
10.4.2. Likely Partners
10.4.3. Less Likely Partners
10.4.4. Least Likely Partners
10.5. Potential Strategic Partners in Europe
10.5.1. Most Likely Partners
10.5.2. Likely Partners
10.5.3. Less Likely Partners
10.5.4. Least Likely Partners
10.6. Potential Strategic Partners in Asia-Pacific and Rest of the World
10.6.1. Most Likely Partners
10.6.2. Likely Partners
10.6.3. Less Likely Partners
10.6.4. Least Likely Partners
11. BRAND POSITIONING ANALYSIS
11.1. Chapter Overview
11.2 Scope and Methodology
11.3. Key Parameters
11.4. Brand Positioning Matrix: ADC Conjugation Technology Providers
11.4.1. Brand Positioning Matrix: Abzena
11.4.2. Brand Positioning Matrix: Ambrx
11.4.3. Brand Positioning Matrix: Byondis
11.4.4. Brand Positioning Matrix: Creative Biolabs
11.4.5. Brand Positioning Matrix: Eisai
11.4.6. Brand Positioning Matrix: Mersana Therapeutics
11.4.7. Brand Positioning Matrix: Sorrento Therapeutics
11.4.8. Brand Positioning Matrix: Tubulis
12. ADC THERAPEUTICS: MARKET LANDSCAPE
12.1. Chapter Overview
12.2. Antibody Drug Conjugates: Therapies Pipeline
12.2.1. Analysis by Stage of Development
12.2.2. Analysis by Target Disease Indication(s)
12.2.3. Analysis by Therapeutic Area(s)
12.2.4. Analysis by Line of Treatment
12.2.5. Analysis by Dosing Frequency
12.2.6. Analysis by Type of Therapy
12.2.7. Analysis by Target Antigen
12.2.8. Analysis by Antibody Isotype
12.2.9. Analysis by Type of Payload / Cytotoxin / Warhead
12.2.10. Analysis by Type of Payload
12.2.11. Analysis by Linker
12.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)
12.3. Antibody Drug Conjugate: List of Developers
12.3.1. Analysis by Year of Establishment
12.3.2. Analysis by Company Size
12.3.3. Analysis by Location of Headquarters
12.3.4. Analysis by Company size and Location of Headquarters
12.3.5. Most Active Players: Analysis by Number of Therapies
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions
13.3. Forecast Methodology
13.4. Global ADC Linker and Conjugation Technologies Market, Historical, Base and Forecasted Scenario, 2017-2035
13.4.1. ADC Linker and Conjugation Technologies Market: Distribution by Generation of Technology, 2023 and 2035
13.4.1.1. ADC Linker and Conjugation Technologies Market for Third-Generation Technologies 2023-2035
13.4.1.2. ADC Linker and Conjugation Technologies Market for Second-Generation Technologies 2023-2035
13.4.1.3. ADC Linker and Conjugation Technologies Market for Next-Generation Technologies, 2023-2035
13.4.2. ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2023 and 2035
13.4.2.1. ADC Linker and Conjugation Technologies Market for Chemical Conjugation, 2023-2035
13.4.2.2. ADC Linker and Conjugation Technologies Market for Chemoenzymatic Conjugation, 2023-2035
13.4.2.3. ADC Linker and Conjugation Technologies Market for Enzymatic Conjugation, 2023-2035
13.4.3. ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2023 and 2035
13.4.3.1. ADC Linker and Conjugation Technologies Market for Cleavable Linkers, 2023-2035
13.4.3.2. ADC Linker and Conjugation Technologies Market for Non-Cleavable Linkers, 2023-2035
13.4.4. ADC Linker and Conjugation Technologies Market: Distribution by Type of Payment Model Adopted, 2023 and 2035
13.4.4.1. ADC Linker and Conjugation Technologies Market for Upfront Payments, 2023-2035
13.4.4.2. ADC Linker and Conjugation Technologies Market for Milestone Payments, 2023-2035
13.4.5. ADC Linker and Conjugation Technologies Market: Distribution by Key Geographical Regions, 2023 and 2035
13.4.5.1. ADC Linker and Conjugation Technologies Market in North America, 2023-2035
13.4.5.1.1. ADC Linker and Conjugation Technologies Market in North America: Distribution by Generation of Technology, 2023-2035
13.4.5.1.2. ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2023-2035
13.4.5.1.3. ADC Linker and Conjugation Technologies Market in North America: Distribution by Type Linker, 2023-2035
13.4.5.2. ADC Linker and Conjugation Technologies Market in Europe, 2023-2035
13.4.5.2.1. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Generation of Technology, 2023-2035
13.4.5.2.2. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2023-2035
13.4.5.2.3. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type Linker, 2023-2035
13.4.5.3. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World, 2023-2035
13.4.5.3.1. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Generation of Technology, 2023-2035
13.4.5.3.2. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Conjugation, 2023-2035
13.4.5.3.3. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Linker, 2023-2035
13.5. Concluding Remarks
14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Abzena
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Saptarshi Ghosh (Scientist II)
14.3. MedLink Therapeutics
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Jiaqiang Cai (Co-Founder and Chief Scientific Officer)
14.4. Merck KGaA
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Kai Uhrig (Head of Strategy and Business Development)
14.5. Singzyme
14.5.1. Company Snapshot
14.5.2. Interview Transcript: Cedric Lizin (Board Member)
14.6. Ajinomoto
14.6.1. Company Snapshot
14.6.2. Interview Transcript: Okuzumi-Tatsuya (General Manager, Research and Development), Brian Mendelsohn (Director of ADC Process Development and Tech Transfer)
14.7. Eucodis Bioscience
14.7.1. Company Snapshot
14.7.2. Interview Transcript: Jan Modregger (Head of Research and Development)
14.8. NBE-Therapeutics
14.8.1. Company Snapshot
14.8.2. Interview Transcript: Wouter Verhoeven (Former Chief Business Officer)
14.9. Shanghai Miracogen
14.9.1. Company Snapshot
14.9.2. Interview Transcript: Mary Chaohong Hu (Chief Executive Officer)
14.10. Synaffix
14.10.1. Company Snapshot
14.10.2. Interview Transcript: Floris van Delft (Chief Scientific Officer)
15. CONCLUDING REMARKS
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Current Market Landscape of ADC Linker and Conjugation Technologies
Figure 2.2 Executive Summary: Patent Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Business Model Analysis
Figure 2.5 Executive Summary: Case Study on ADC Therapeutics
Figure 2.6 Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1. Components of ADCs
Figure 3.2. Types of Linkers
Figure 4.1. ADC Linker and Conjugation Technologies: Distribution by Type of Technology
Figure 4.2. ADC Linker and Conjugation Technologies: Distribution by Availability of Licensing
Figure 4.3. ADC Conjugation Technologies: Distribution by Generation of Technology
Figure 4.4. ADC Conjugation Technologies: Distribution by Site Specificity
Figure 4.5. ADC Conjugation Technologies: Distribution by Type of Conjugation
Figure 4.6. ADC Conjugation Technologies: Distribution by Drug Antibody Ratio
Figure 4.7. ADC Conjugation Technologies: Distribution by Compatible Linker
Figure 4.8. ADC Conjugation Technologies: Distribution by Conjugation Chemistry
Figure 4.9. ADC Conjugation Technologies: Distribution by Conjugation Site
Figure 4.10. ADC Linker and ADC Linker-Payload Technologies: Distribution by Type of Linker
Figure 4.11. ADC Linker and Conjugation Technology Providers: Distribution by Year of Establishment
Figure 4.12 ADC Linker and Conjugation Technology Providers: Distribution by Company Size
Figure 4.13. ADC Linker and Conjugation Technology Providers: Distribution by Location of Headquarters
Figure 4.14. ADC Linker and Conjugation Technology Providers: Distribution by Year of Establishment and Location of Headquarters
Figure 4.15. ADC Linker and Conjugation Technology Providers: Distribution by Company Size and Location of Headquarters
Figure 5.1 Technology Competitiveness Analysis: Distribution of Technologies Offered by Small Companies
Figure 5.2 Technology Competitiveness Analysis: Distribution of Technologies Offered by Mid-sized Companies
Figure 5.3 Technology Competitiveness Analysis: Distribution of Technologies Offered by Large Companies
Figure 6.1 Ambrx: Annual Revenues, 2020-2022 (USD Million)
Figure 6.2 Catalent Biologics: Revenues, 2018- 2022 (USD Billion)
Figure 6.3. Mersana Therapeutics: Annual Revenues, 2018-2022 (USD Million)
Figure 6.4 Seagen: Revenues, 2018-2022 (USD Billion)
Figure 6.5 Sutro Biopharma: Revenues, 2018 - 2022 (KRW Billion)
Figure 6.6 Heidelberg Pharma: Annual Revenues, 2018-2022 (EUR Million)
Figure 7.1. Patent Analysis: Distribution by Type of Patent
Figure 7.2. Patent Analysis: Cumulative Distribution by Publication Year
Figure 7.3. Patent Analysis: Cumulative Distribution by Application Year
Figure 7.4. Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications
Figure 7.5. Patent Analysis: Distribution by Patent Jurisdiction
Figure 7.6. Patent Analysis: Distribution by CPC Symbols and Sections
Figure 7.7. Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 7.9. Leading Industry Players: Distribution by Number of Patents
Figure 7.10. Leading Non-Industry Players: Distribution by Number of Patents
Figure 7.11. Leading Patent Assignees: Distribution by Number of Patents
Figure 7.12. Patent Benchmarking Analysis: Distribution of Leading Industry Player by Patent Characteristics (CPC Codes)
Figure 7.13. Patent Analysis: Distribution by Patent Age
Figure 7.14. ADC Linker and Conjugation Technologies: Patent Valuation
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Generation of Technology
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Linker
Figure 8.6. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Conjugation
Figure 8.7. Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.8. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 8.9. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.10. Partnerships and Collaborations: Distribution by Therapeutic Area(s)
Figure 8.11. Most Active Players: Distribution by Number of Partnerships
Figure 8.12. Most Popular Technologies: Distribution by Number of Partnerships
Figure 8.13 Partnerships and Collaborations: Local and International Agreements
Figure 8.14 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Business Models Analysis: Distribution by Purpose of Partnership
Figure 9.2 Business Models Analysis: Year-wise Distribution by Purpose of Partnership
Figure 9.3 Business Models Analysis: Distribution by Type of Business Strategy Adopted
Figure 9.4 Business Models Analysis: Distribution by Purpose of Partnership and Type of Business Strategy Adopted
Figure 9.5 Business Models Analysis: Distribution by Upfront and Milestone Payments
Figure 9.6. Business Models Analysis: Distribution by Type of Business Strategy Adopted and Deal Value
Figure 9.7. Synaffix: Distribution by Purpose of Partnership
Figure 9.8. Synaffix: Distribution of Technology Out-Licensing Deals by Deal Value
Figure 9.9. LegoChem Biosciences: Distribution by Purpose of Partnership
Figure 9.10. LegoChem Biosciences: Distribution by Year of Partnership and Business Strategy Adopted
Figure 9.11. LegoChem Biosciences: Distribution of Technology Out-Licensing Deals by Deal Value
Figure 9.12. Catalent Biologics: Distribution by Purpose of Partnership
Figure 9.13. Catalent Biologics: Distribution by Year of Partnership and Business Strategy Adopted
Figure 9.14. Sutro Biopharma: Distribution by Purpose of Partnership
Figure 9.15. Sutro Biopharma: Distribution by Year of Partnership and Business Strategy Adopted
Figure 9.16. Sutro Biopharma: Distribution of Technology Out-Licensing Deals by Deal Value
Figure 9.17. Heidelberg Pharma: Distribution by Purpose of Partnership
Figure 9.18. Heidelberg Pharma: Distribution by Year of Partnership and Business Strategy Adopted
Figure 9.19. Mersana Therapeutics: Distribution by Purpose of Partnership
Figure 9.20. Mersana Therapeutics: Distribution by Year of Partnership and Business Strategy Adopted
Figure 11.1 Brand Positioning Analysis: Competitive Advantage
Figure 11.2 Brand Positioning Analysis: Reasons to Believe
Figure 11.3 Brand Positioning Matrix: Abzena
Figure 11.4 Brand Positioning Matrix: Ambrx
Figure 11.5 Brand Positioning Matrix: Byondis
Figure 11.6. Brand Positioning Matrix: Creative Biolabs
Figure 11.7. Brand Positioning Matrix: Eisai
Figure 11.8. Brand Positioning Matrix: Mersana Therapeutics
Figure 11.9. Brand Positioning Matrix: Sorrento Therapeutics
Figure 11.10. Brand Positioning Matrix: Tubulis
Figure 12.1. Antibody Drug Conjugates: Distribution by Stage of Development
Figure 12.2. Antibody Drug Conjugates: Distribution by Target Disease Indication(s)
Figure 12.3. Antibody Drug Conjugates: Distribution by Therapeutic Area(s)
Figure 12.4. Antibody Drug Conjugates: Distribution by Line of Treatment
Figure 12.5. Antibody Drug Conjugates: Distribution by Dosing Frequency
Figure 12.6. Antibody Drug Conjugates: Distribution by Type of Therapy
Figure 12.7. Antibody Drug Conjugates: Distribution by Target Antigen
Figure 12.8. Antibody Drug Conjugates: Distribution by Antibody Isotype
Figure 12.9. Antibody Drug Conjugates: Distribution by Type of Cytotoxin / Warhead
Figure 12.10. Antibody Drug Conjugates: Distribution by Type of Payload
Figure 12.11. Antibody Drug Conjugates: Distribution by Linker
Figure 12.12 Antibody Drug Conjugates: Distribution by Type of Linker
Figure 12.13. Antibody Drug Conjugate Developers: Distribution by Year of Establishment
Figure 12.14. Antibody Drug Conjugates Developers: Distribution by Company Size
Figure 12.15. Antibody Drug Conjugates Developers: Distribution by Location of Headquarters
Figure 12.16. Antibody Drug Conjugates Developers: Distribution by Company Size and Location of Headquarters
Figure 12.17. Most Active Players: Distribution by Number of Therapies
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 Technology Licensing Deal: Payment Structure
Figure 13.3 Global ADC Linker and Conjugation Technologies Market, Historical, Base and Forecasted Scenario, 2023-2035 (USD Million)
Figure 13.4 ADC Linker and Conjugation Technologies Market: Distribution by Generation of Technology, 2023 and 2035
Figure 13.5 ADC Linker and Conjugation Technologies Market for Third-Generation Technologies, 2023-2035 (USD Million)
Figure 13.6 ADC Linker and Conjugation Technologies Market for Second-Generation Technologies, 2023-2035 (USD Million)
Figure 13.7 ADC Linker and Conjugation Technologies Market for Next-Generation Technologies, 2023-2035 (USD Million)
Figure 13.8 ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2023 and 2035
Figure 13.9 ADC Linker and Conjugation Technologies Market for Chemical Conjugation, 2023-2035 (USD Million)
Figure 13.10 ADC Linker and Conjugation Technologies Market for Chemoenzymatic Conjugation, 2023-2035 (USD Million)
Figure 13.11 ADC Linker and Conjugation Technologies Market for Enzymatic Conjugation, 2023-2035 (USD Million)
Figure 13.12 ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2023 and 2035
Figure 13.13 ADC Linker and Conjugation Technologies Market for Cleavable Linkers, 2023-2035 (USD Million)
Figure 13.14 ADC Linker and Conjugation Technologies Market for Non-Cleavable Linkers, 2023-2035 (USD Million)
Figure 13.15 ADC Linker and Conjugation Technologies Market: Distribution by Type of Payment Model Adopted, 2023 and 2035
Figure 13.16 ADC Linker and Conjugation Technologies Market for Upfront Payments, 2023-2035 (USD Million)
Figure 13.17 ADC Linker and Conjugation Technologies Market for Milestone Payments, 2023-2035 (USD Million)
Figure 13.18 ADC Linker and Conjugation Technologies Market: Distribution by Key Geographical Regions, 2023 and 2035
Figure 13.19 ADC Linker and Conjugation Technologies Market in North America, 2023-2035 (USD Million)
Figure 13.20 ADC Linker and Conjugation Technologies Market in North America: Distribution by Generation of Technology, 2023-2035 (USD Million)
Figure 13.21 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2023-2035 (USD Million)
Figure 13.22 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type Linker, 2023-2035 (USD Million)
Figure 13.23 ADC Linker and Conjugation Technologies Market in Europe, 2023-2035 (USD Million)
Figure 13.24 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Generation of Technology, 2023-2035 (USD Million)
Figure 13.25 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2023-2035 (USD Million)
Figure 13.26 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type Linker, 2023-2035 (USD Million)
Figure 13.27 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World, 2023-2035 (USD Million)
Figure 13.28 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Generation of Technology, 2023-2035 (USD Million)
Figure 13.29 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Conjugation, 2023-2035 (USD Million)
Figure 13.30 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type Linker, 2023-2035 (USD Million)
Figure 15.1 Concluding Remarks: Current Market Landscape of ADC Linker and Conjugation Technologies
Figure 15.2 Concluding Remarks: Patent Analysis
Figure 15.3 Concluding Remarks: Partnerships and Collaborations
Figure 15.4 Concluding Remarks: Business Model Analysis
Figure 15.5 Concluding Remarks: Current Market Landscape of ADC Therapeutics
Figure 15.6 Concluding Remarks: Market Sizing and Opportunity Analysis
Table 3.1. Commonly Used Cytotoxins in ADC Therapeutics
Table 3.2 OEL Bands: Guidelines by SafeBridge Consultants
Table 4.1. ADC Linker and Conjugation Technologies: Overall Market Landscape
Table 4.2. ADC Conjugation Technologies: Information on Generation of Technology, Site-Specificity, Type of Conjugation and Drug Antibody Ratio
Table 4.3. ADC Conjugation Technologies: Information on Number of Steps Involved, Compatible Linker, Conjugation Chemistry and Conjugation Site
Table 4.4. ADC Linker and Linker-Payload Technologies: Information on Type of Linker and Linker Name
Table 4.5. ADC Linker and Conjugation Technologies: List of Technology Providers
Table 4.6. ADC Linker and Conjugation Technologies: List of Service Providers
Table 6.1. ADC Linkers and Conjugation Technologies: List of Profiled Companies
Table 6.2. Ambrx: Company Overview
Table 6.3. Ambrx: ADC Linkers and Conjugation Technologies Portfolio
Table 6.4. Ambrx: Antibody Drug Conjugates Portfolio
Table 6.5. Ambrx: Recent Developments and Future Outlook
Table 6.6. Catalent Biologics: Company Overview
Table 6.7. Catalent Biologics: ADC Linkers and Conjugation Technologies Portfolio
Table 6.8. Catalent Biologics: Antibody Drug Conjugates Portfolio
Table 6.9. Catalent Biologics: Recent Developments and Future Outlook
Table 6.10. Mersana Therapeutics: Company Overview
Table 6.11. Mersana Therapeutics: ADC Linkers and Conjugation Technologies Portfolio
Table 6.12. Mersana Therapeutics: Antibody Drug Conjugates Portfolio
Table 6.13. Mersana Therapeutics: Recent Developments and Future Outlook
Table 6.14. Seagen: Company Overview
Table 6.15. Seagen: ADC Linkers and Conjugation Technologies Portfolio
Table 6.16. Seagen: Antibody Drug Conjugates Portfolio
Table 6.17. Seagen: Recent Developments and Future Outlook
Table 6.18. Sutro Biopharma: Company Overview
Table 6.19. Sutro Biopharma: ADC Linkers and Conjugation Technologies Portfolio
Table 6.20. Sutro Biopharma: Antibody Drug Conjugates Portfolio
Table 6.21. Sutro Biopharma: Recent Developments and Future Outlook
Table 6.22. Antikor: Company Overview
Table 6.23. Antikor: ADC Conjugation Technology Portfolio
Table 6.24. Antikor: Antibody Drug Conjugates Portfolio
Table 6.25. Antikor: Recent Developments and Future Outlook
Table 6.26. Iksuda Therapeutics: Company Overview
Table 6.27. Iksuda Therapeutics: ADC Linkers and Conjugation Technologies Portfolio
Table 6.28. Iksuda Therapeutics: Antibody Drug Conjugates Portfolio
Table 6.29. Heidelberg Pharma: Company Overview
Table 6.30. Heidelberg Pharma: ADC Linkers and Conjugation Technologies Portfolio
Table 6.31. Heidelberg Pharma: Antibody Drug Conjugates Portfolio
Table 6.32. Heidelberg Pharma: Recent Developments and Future Outlook
Table 6.33. LinXis: Company Overview
Table 6.34. LinXis: ADC Conjugation Technology Portfolio
Table 6.35. NBE-Therapeutics: Company Overview
Table 6.36. NBE-Therapeutics: ADC Linkers and Conjugation Technologies Portfolio
Table 6.37. NBE-Therapeutics: Antibody Drug Conjugates Portfolio
Table 6.38. Alteogen: Company Overview
Table 6.39. Alteogen: ADC Linkers and Conjugation Technologies Portfolio
Table 6.40. Alteogen: Antibody Drug Conjugates Portfolio
Table 6.41. LegoChem Biosciences: Company Overview
Table 6.42. LegoChem Biosciences: ADC Linkers and Conjugation Technologies Portfolio
Table 6.43. LegoChem Biosciences: Antibody Drug Conjugates Portfolio
Table 6.44. LegoChem Biosciences: Recent Developments and Future Outlook
Table 7.1. Patent Analysis: Top CPC Sections
Table 7.2. Patent Analysis: Top CPC Symbols
Table 7.3. Patent Analysis: Top CPC Codes
Table 7.4. Patent Analysis: Summary of Benchmarking Analysis
Table 7.5. Patent Analysis: Categorization based on Weighted Valuation Scores
Table 7.6. Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 8.1. ADC Linker and Conjugation Technologies: Partnerships and Collaborations
Table 8.2. ADC Linker and Conjugation Technologies: Partnerships and Collaborations, Information on Type of Partner, Therapeutic Area(s) and Type of Agreement (Region-wise and Geography-wise)
Table 9.1. ADC Linker and Conjugation Technologies: Business Model Analysis
Table 10.1. North America: Most Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.2. North America: Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.3. North America: Less Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.4. North America: Least Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.5. Europe: Most Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.6. Europe: Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.7. Europe: Less Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.8. Europe: Least Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.9. Asia-Pacific and Rest of the World: Most Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.10. Asia-Pacific and Rest of the World: Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.11. Asia-Pacific and Rest of the World: Less Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.12. Asia-Pacific and Rest of the World: Least Likely Partners for ADC Linker and Conjugation Technology Providers
Table 12.1. Antibody Drug Conjugates: Information on Drug Candidates, Developer(s), Stage of Development, Target Disease Indication(s) and Therapeutics Area(s)
Table 12.2. Antibody Drug Conjugates: Information on Drug Candidates, Line of Treatment, Dosage Frequency, Type of Therapy, Target Antigen and Antibody Isotype
Table 12.3. Antibody Drug Conjugates: Information on Drug Candidates, Payload / Cytotoxin / Warhead, Type of Payload, Linker and Type of Linker (Cleavable and Non-Cleavable)
Table 12.4. Antibody Drug Conjugate Developers: Information on Year of Establishment, Company Size, Location of Headquarters
Table 13.1. Technology Licensing Deal: Tranches of Milestone Payments
Table 13.2. ADC Linker and Conjugation Technologies: Average Upfront Payments and Average Milestone Payments (USD Million)
Table 14.1 Abzena: Company Snapshot
Table 14.2. MedLink Therapeutics: Company Snapshot
Table 14.3 Merck KGaA: Company Snapshot
Table 14.4 Singzyme: Company Snapshot
Table 14.5 Ajinomoto: Company Snapshot
Table 14.6 Eucodis Bioscience: Company Snapshot
Table 14.7 NBE-Therapeutics: Company Snapshot
Table 14.8 Shanghai Miracogen: Company Snapshot
Table 14.9 Synaffix: Company Snapshot
Table 16.1 ADC Linker and Conjugation Technologies: Distribution by Type of Technology
Table 16.2 ADC Linker and Conjugation Technologies: Distribution by Availability of Licensing
Table 16.3 ADC Conjugation Technologies: Distribution by Generation of Technology
Table 16.4 ADC Conjugation Technologies: Distribution by Site Specificity
Table 16.5 ADC Conjugation Technologies: Distribution by Type of Conjugation
Table 16.6 ADC Conjugation Technologies: Distribution by Drug Antibody Ratio
Table 16.7 ADC Conjugation Technologies: Distribution by Compatible Linker
Table 16.8 ADC Conjugation Technologies: Distribution by Conjugation Chemistry
Table 16.9 ADC Conjugation Technologies: Distribution by Conjugation Site
Table 16.10 ADC Linker and ADC Linker-Payload Technologies: Distribution by Type of Linker
Table 16.11 ADC Linker and Conjugation Technology Providers: Distribution by Year of Establishment
Table 16.12 ADC Linker and Conjugation Technology Providers: Distribution by Company Size
Table 16.13 ADC Linker and Conjugation Technology Providers: Distribution by Location of Headquarters
Table 16.14 ADC Linker and Conjugation Technology Providers: Distribution by Year of Establishment and Location of Headquarters
Table 16.15 ADC Linker and Conjugation Technology Providers: Distribution by Company Size and Location of Headquarters
Table 16.16 Ambrx: Annual Revenues, 2020-2022 (USD Million)
Table 16.17 Mersana Therapeutics: Annual Revenues, 2018-2022 (USD Million)
Table 16.18 Seagen: Revenues, 2018-2022 (USD Billion)
Table 16.19 Sutro Biopharma: Revenues, 2018 - 2022 (KRW Billion)
Table 16.20 Heidelberg Pharma: Annual Revenues, 2018-2022 (EUR Million)
Table 16.21 Catalent Biologics: Revenues, 2018- 2022 (USD Billion)
Table 16.22 Patent Analysis: Distribution by Type of Patent
Table 16.23 Patent Analysis: Cumulative Distribution by Publication Year
Table 16.24 Patent Analysis: Cumulative Distribution by Application Year
Table 16.25 Patent Analysis: Distribution by Patent Type and Publication Year
Table 16.26 Patent Analysis: Distribution by Patent Jurisdiction
Table 16.27 Patent Analysis: Distribution by CPC Symbols and Sections
Table 16.28 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 16.29 Leading Industry Players: Distribution by Number of Patents
Table 16.30 Leading Non-Industry Players: Distribution by Number of Patents
Table 16.31 Leading Individual Assignees: Distribution by Number of Patents
Table 16.32 Patent Benchmarking Analysis: Distribution of Leading Industry Player by Patent Characteristics (CPC Codes)
Table 16.33 Patent Analysis: Distribution by Patent Age
Table 16.34 ADC Linker and Conjugation Technologies: Patent Valuation
Table 16.35 Partnerships and Collaborations: Distribution by Year of Partnership
Table 16.36 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.37 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 16.38 Partnerships and Collaborations: Distribution by Type of Partnership and Generation of Technology
Table 16.39 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Linker
Table 16.40 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Conjugation
Table 16.41 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.42 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 16.43 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 16.44 Partnerships and Collaborations: Distribution by Therapeutic Area(s)
Table 16.45 Most Active Players: Distribution by Number of Partnerships
Table 16.46 Most Popular Technologies: Distribution by Number of Partnerships
Table 16.47 Partnership and Collaborations: Local and International Agreements
Table 16.48 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.49 Business Models Analysis: Distribution by Purpose of Partnership
Table 16.50 Business Models Analysis: Distribution by Year of Partnership and Purpose of Partnership
Table 16.51 Business Models Analysis: Distribution by Type of Business Strategy Adopted
Table 16.52 Business Models Analysis: Distribution by Purpose of Partnership and Type of Business Strategy Adopted
Table 16.53 Business Models Analysis: Distribution by Upfront and Milestone Payments
Table 16.54 Business Models Analysis: Distribution by Type of Business Model Adopted and Deal Value
Table 16.55 Synaffix: Distribution by Purpose of Partnership
Table 16.56 Synaffix: Technology Out-Licensing Deals by Deal Value
Table 16.57 LegoChem Biosciences: Distribution by Purpose of Partnership
Table 16.58 LegoChem Biosciences: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.59 LegoChem Biosciences: Distribution of Technology Out-Licensing Deals by Deal Value
Table 16.60 Catalent Biologics: Distribution by Purpose of Partnership
Table 16.61 Catalent Biologics: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.62 Sutro Biopharma: Distribution by Purpose of Partnership
Table 16.63. Sutro Biopharma: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.64. Sutro Biopharma: Distribution of Technology Out-Licensing Deals by Deal Value
Table 16.65. Heidelberg Pharma: Distribution by Purpose of Partnership
Table 16.66. Heidelberg Pharma: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.67. Mersana Therapeutics: Distribution by Purpose of Partnership
Table 16.68. Mersana Therapeutics: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.69. Antibody Drug Conjugates: Distribution by Stage of Development
Table 16.70. Antibody Drug Conjugates: Distribution by Target Disease Indication
Table 16.71. Antibody Drug Conjugates: Distribution by Therapeutic Area(s)
Table 16.72. Antibody Drug Conjugates: Distribution by Line of Treatment
Table 16.73. Antibody Drug Conjugates: Distribution by Dosing Frequency
Table 16.74. Antibody Drug Conjugates: Distribution by Type of Therapy
Table 16.75. Antibody Drug Conjugates: Distribution by Target Antigen
Table 16.76. Antibody Drug Conjugates: Distribution by Antibody Isotype
Table 16.77. Antibody Drug Conjugates: Distribution by Type of Cytotoxin / Warhead
Table 16.78. Antibody Drug Conjugates: Distribution by Type of Payload
Table 16.79. Antibody Drug Conjugates: Distribution by Linker
Table 16.80 Antibody Drug Conjugates: Distribution by Type of Linker
Table 16.81. Antibody Drug Conjugate Developers: Distribution by Year of Establishment
Table 16.82. Antibody Drug Conjugates Developers: Distribution by Company Size
Table 16.83. Antibody Drug Conjugates Developers: Distribution by Location of Headquarters
Table 16.84. Antibody Drug Conjugates Developers: Distribution by Company Size and Location of Headquarters
Table 16.85. Most Active Players: Distribution by Number of Antibody Drug Conjugates
Table 16.86 Global ADC Linker and Conjugation Technologies Market, Conservative, Base and Optimistic Scenarios, 2017-2035 (USD Million)
Table 16.87 ADC Linker and Conjugation Technologies Market: Distribution by Generation of Technology, 2023 and 2035
Table 16.88 ADC Linker and Conjugation Technologies Market for Third-Generation Technologies, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.89 ADC Linker and Conjugation Technologies Market for Second-Generation Technologies, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.90 ADC Linker and Conjugation Technologies Market for Next-Generation Technologies, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.91 ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2023 and 2035
Table 16.92 ADC Linker and Conjugation Technologies Market for Chemical Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.93 ADC Linker and Conjugation Technologies Market for Chemoenzymatic Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.94 ADC Linker and Conjugation Technologies Market for Enzymatic Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.95 ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2023 and 2035
Table 16.96 ADC Linker and Conjugation Technologies Market for Cleavable Linkers, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.97 ADC Linker and Conjugation Technologies Market for Non-Cleavable Linkers, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.98 ADC Linker and Conjugation Technologies Market: Distribution by Type of Payment Model Adopted, 2023 and 2035
Table 16.99 ADC Linker and Conjugation Technologies Market for Upfront Payments, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.100 ADC Linker and Conjugation Technologies Market for Milestone Payments, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.101 ADC Linker and Conjugation Technologies Market: Distribution by Key Geographical Regions, 2023 and 2035
Table 16.102 ADC Linker and Conjugation Technologies Market in North America, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.103 ADC Linker and Conjugation Technologies Market in North America: Distribution by Generation of Technology, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.104 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.105 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type Linker 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.106 ADC Linker and Conjugation Technologies Market in Europe, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.107 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Generation of Technology, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.108 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.109 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type Linker 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.110 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.111 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Generation of Technology, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.112 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.113 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type Linker 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
The following companies / institutes / government bodies and organizations have been mentioned in this report:
Source 1: https://pubs.rsc.org/en/content/articlehtml/2017/sc/c6sc05149a
Source 2: https://aacrjournals.org/clincancerres/article/17/20/6389/76679/Antibody-Conjugate-Therapeutics-Challenges-and
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES